Equities research analysts forecast that pSivida Corp. (NASDAQ:PSDV) will announce earnings per share (EPS) of ($0.16) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for pSivida Corp.’s earnings. The lowest EPS estimate is ($0.17) and the highest is ($0.14). pSivida Corp. posted earnings of ($0.19) per share in the same quarter last year, which would suggest a positive year over year growth rate of 15.8%. The firm is expected to report its next earnings report on Monday, September 11th.
According to Zacks, analysts expect that pSivida Corp. will report full-year earnings of ($0.51) per share for the current year, with EPS estimates ranging from ($0.53) to ($0.50). For the next financial year, analysts forecast that the firm will report earnings of ($0.56) per share, with EPS estimates ranging from ($0.69) to ($0.42). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover pSivida Corp..
Several analysts recently weighed in on the company. HC Wainwright set a $8.00 price target on pSivida Corp. and gave the company a “buy” rating in a report on Wednesday, June 14th. Ladenburg Thalmann Financial Services set a $13.00 price target on pSivida Corp. and gave the company a “buy” rating in a report on Wednesday, June 14th. FBR & Co restated a “buy” rating on shares of pSivida Corp. in a report on Wednesday, June 14th. Rodman & Renshaw assumed coverage on pSivida Corp. in a report on Tuesday, May 30th. They set a “buy” rating and a $8.00 price target on the stock. Finally, Northland Securities set a $10.00 price target on pSivida Corp. and gave the company a “buy” rating in a report on Wednesday, June 14th. Five research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and a consensus price target of $8.60.
In related news, insider Nancy Lurker purchased 56,700 shares of the firm’s stock in a transaction that occurred on Wednesday, June 14th. The shares were bought at an average price of $1.76 per share, for a total transaction of $99,792.00. Following the acquisition, the insider now owns 56,700 shares of the company’s stock, valued at approximately $99,792. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 2.59% of the company’s stock.
An institutional investor recently bought a new position in pSivida Corp. stock. OxFORD Asset Management LLP bought a new position in pSivida Corp. (NASDAQ:PSDV) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 69,004 shares of the company’s stock, valued at approximately $118,000. OxFORD Asset Management LLP owned 0.18% of pSivida Corp. at the end of the most recent quarter. 20.13% of the stock is owned by hedge funds and other institutional investors.
pSivida Corp. (NASDAQ PSDV) traded down 1.85% on Thursday, hitting $1.06. 126,464 shares of the company’s stock traded hands. The stock has a 50 day moving average price of $1.37 and a 200-day moving average price of $1.72. The stock’s market cap is $41.62 million. pSivida Corp. has a 12 month low of $1.04 and a 12 month high of $4.03.
ILLEGAL ACTIVITY WARNING: This piece was reported by Daily Political and is owned by of Daily Political. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/08/17/1398647.html.
pSivida Corp. Company Profile
pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for pSivida Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida Corp. and related companies with MarketBeat.com's FREE daily email newsletter.